Celgene | Search Results | Sutro Biopharma, Inc.

New Search

If you are not happy with the results below please do another search

Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference

November 26, 2019

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and... read more →

Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference

November 19, 2019

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and... read more →

Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

November 8, 2019

STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29, 2019 STRO-001... read more →

Sutro Biopharma to Present at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

October 29, 2019

Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer - Data is being presented as a poster... read more →

Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

October 16, 2019

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and... read more →

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

October 8, 2019

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors - Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as Clinical Development Candidate - SOUTH... read more →

Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

September 4, 2019

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C.... read more →

Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

August 14, 2019

STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European Hematology Association (“EHA”) Congress, June 15, 2019 STRO-002 Phase 1 Clinical Trial... read more →

Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference

August 8, 2019

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and... read more →

Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair

June 24, 2019

Former Biogen Idec executive to bring additional strategic expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., June 24, 2019 -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development... read more →

33 Search results for: Celgene

New Search